28 related articles for article (PubMed ID: 8917348)
1. Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets.
Bugelski PJ; Martin PL
Br J Pharmacol; 2012 Jun; 166(3):823-46. PubMed ID: 22168282
[TBL] [Abstract][Full Text] [Related]
2. Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin.
Zand MS; Vo T; Pellegrin T; Felgar R; Liesveld JL; Ifthikharuddin JJ; Abboud CN; Sanz I; Huggins J
Blood; 2006 Apr; 107(7):2895-903. PubMed ID: 16368890
[TBL] [Abstract][Full Text] [Related]
3. Anti-human interleukin-6 receptor antibody inhibits human myeloma growth in vivo.
Suzuki H; Yasukawa K; Saito T; Goitsuka R; Hasegawa A; Ohsugi Y; Taga T; Kishimoto T
Eur J Immunol; 1992 Aug; 22(8):1989-93. PubMed ID: 1639101
[TBL] [Abstract][Full Text] [Related]
4. [Growth characteristics of a human myeloma cell line transfected with IL-6 cDNA].
Takahashi T; Okuno Y; Ohsugi Y
Rinsho Ketsueki; 1993 Apr; 34(4):423-6. PubMed ID: 8510328
[TBL] [Abstract][Full Text] [Related]
5. [Effect of humanized anti-interleukin-6 receptor antibody on new xenograft model of multiple myeloma].
Shimazaki C; Goto H
Rinsho Ketsueki; 1997 Apr; 38(4):281-4. PubMed ID: 9146051
[No Abstract] [Full Text] [Related]
6. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
[TBL] [Abstract][Full Text] [Related]
7. Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
Campo S; Serlupi-Crescenzi O; Arseni B; Rossi S; Saggio I; Salone B; Cherubini G; Carminati P; De Santis R
Cytokine; 2005 Sep; 31(5):368-74. PubMed ID: 16061391
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: antitumor activity in xenograft model of multiple myeloma.
Tsunenari T; Akamatsu K; Kaiho S; Sato K; Tsuchiya M; Koishihara Y; Kishimoto T; Ohsugi Y
Anticancer Res; 1996; 16(5A):2537-44. PubMed ID: 8917348
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of multiple myeloma.
Huang YW; Vitetta ES
Stem Cells; 1995 Mar; 13(2):123-34. PubMed ID: 7540468
[TBL] [Abstract][Full Text] [Related]
10. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
11. [Advances in the pathogenesis, biology, and management of multiple myeloma].
Kosaka M
Rinsho Byori; 1996 Aug; 44(8):743-9. PubMed ID: 8816060
[TBL] [Abstract][Full Text] [Related]
12. [Clinical application of interleukin-6 receptor antibody].
Nishimoto N; Shima Y; Sasai M; Danno N; Yoshizaki K
Nihon Rinsho Meneki Gakkai Kaishi; 1997 Apr; 20(2):87-94. PubMed ID: 9280606
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]